Clinical Reference Lab News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Co-Diagnostics turns 1Q net profit of nearly $8M on strong sales of its Logix Smart COVID-19 Test Fueled by $20 million in revenue, net income was $7.9 million as compared to a net loss of $1.1 million in the prior-year quarter Looking to the second quarter, Co-Diagnostics gave revenue guidance in the range of $20 million to $22 million Co-Diagnostics Inc (NASDAQ:CODX) reported that it earned a first-quarter net profit -- versus a loss last year -- on strong sales of its Logix Smart COVID-19 Test. For the quarter ended March 31, the company said income before taxes was $9.9 mill...

Share this article SALT LAKE CITY, May 13, 2021 /PRNewswire/ -- Co-Diagnostics, Inc.  (NASDAQ: CODX), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today financial results for the first quarter ended March 31, 2021. First-Quarter 2021 Financial Results: Strong quarterly results highlighted by revenue of $20.0 million, pre-tax income of $9.9 million, diluted EPS of $0.26 Revenue of $20.0 million, primarily due to sales of the Logix Smart™ COVID-19 Test Gross profit increased to $16.8 million, representing 83.7...

NA Proactive news snapshot: Zynerba Pharmaceuticals, Nerds On Site, Marvel Discovery, Water Tower Research UPDATE … A glance at some of the day's highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting. The first poster is titled, “Cannabidiol in Fragile X Syndrom...

NA Proactive news snapshot: Zynerba Pharmaceuticals, Nerds On Site, Marvel Discovery, Water Tower Research UPDATE … A glance at some of the day's highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting. The first poster is titled, “Cannabidiol in Fragile X Syndrom...

NA Proactive news snapshot: Zynerba Pharmaceuticals, Nerds On Site, Marvel Discovery, Water Tower Research UPDATE … A glance at some of the day's highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive Zynerba Pharmaceuticals Inc (NASDAQ:ZYNE), the leader in pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, is presenting two posters at the Society of Biological Psychiatry (SOBP) 2021 Virtual Meeting. The first poster is titled, “Cannabidiol in Fragile X Syndrom...